Article thumbnail

Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series

By Alfred P See, Jing Zeng, Phuoc T Tran and Michael Lim
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). A: HIV infection and lymphoma.
  2. (2010). A: Radiotherapy for Patients With the Human Immunodeficiency Virus: Are Special Precautions Necessary? Cancer
  3. (2007). Abrams DI: AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Current Opinion in Oncology
  4. (2008). AK: Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.
  5. (2005). al: Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer
  6. (2007). CD: HIV protease inhibitors enhance the efficacy of irradiation. Cancer Research
  7. (2003). Cervical neoplasia and the HIV-infected patient. HematologyOncology Clinics of North America
  8. (2005). Chene G: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
  9. (2009). Clin Epidemiology Grp F-AC: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncology
  10. (2005). CY: Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. Jaids-Journal of Acquired Immune Deficiency Syndromes
  11. (2002). DE: Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Research
  12. (2005). Deutsch E: Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor Ritonavir in a head and neck carcinoma model. Anticancer Research
  13. (2009). DR: Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-hpv-infected cell line and relationship to signaling through AKT.
  14. (2010). EA: Age at Cancer Diagnosis Among Persons With AIDS in the United States. Annals of Internal Medicine
  15. (2005). EJ: Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Research
  16. (2004). EJ: The influence of Ras pathway signaling on tumor radiosensitivity. Cancer and Metastasis Reviews
  17. (2010). Engels EA: Cancer as a Cause of Death among People with AIDS in the United States. Clinical Infectious Diseases
  18. (2006). et al: Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clinical Cancer Research
  19. (2009). et al: Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir.
  20. (2007). et al: Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clinical Cancer Research
  21. (2007). FR: HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Research
  22. (2008). Giordano SH: Completion of adjuvant radiation therapy among women with breast cancer. Cancer
  23. (1991). Glutathione deficiency and radiosensitivity in AIDS patients. Lancet
  24. (2004). H: HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Molecular Cancer Therapeutics
  25. (2005). H: HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Science
  26. (2005). HaasKogan DA: Hypoxia-induced radioresistance is independent of hypoxiainducible factor-1A in vitro.
  27. (1997). Hinkelbein W: Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection. Acta Oncologica
  28. (1997). HIV-1 protease inhibitors - A review for clinicians.
  29. (2010). Inoue T: The Suppression of Hypoxia-inducible Factor and Vascular Endothelial Growth Factor by siRNA Does not Affect the Radiation Sensitivity of Multicellular Tumor Spheroids.
  30. (2007). Insulin resistance and HIV infection: a review.
  31. (1999). Madoff RD: Malignant tumors of the anal canal - The spectrum of disease, treatment, and outcomes. Cancer
  32. (2006). Maity A: Nelfinavir down-regulates hypoxia-inducible factor 1 alpha and VEGF expression and increases tumor oxygenation: Implications for radiotherapy. Cancer Research
  33. (2007). Montaner JSG: Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. Aids
  34. (2005). Muschel RJ: HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Research
  35. (2006). NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
  36. (2003). Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical Cancer Research
  37. (2006). PAS: Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: Outcomes and toxicities.
  38. (2006). PK: HIV-1 Tat depresses DNA-PKCS expression and DNA repair, and sensitizes cells to ionizing radiation.
  39. (2002). RE: Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy.
  40. (2009). Regner S: The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients. Jaids-Journal of Acquired Immune Deficiency Syndromes
  41. (2008). Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS
  42. (2010). Sartor CI: Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status. Clinical Cancer Research
  43. (2001). Simmang CL: Outcome analysis of HIVpositive patients with anal squamous cell carcinoma. Diseases of the Colon & Rectum
  44. (2004). Simmang CL: Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Diseases of the Colon & Rectum
  45. (2002). Survival of women after breast conserving surgery for early stage breast cancer. Breast Cancer Research and Treatment
  46. (2007). TC: HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Research
  47. (2000). The mechanism of insulin resistance caused by HIV protease inhibitor therapy.
  48. (2005). Tominaga T, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet
  49. (2006). Triservice ACC: Comparisons of causes of death and mortality rates among HIV-infected persons -Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. Jaids-Journal of Acquired Immune Deficiency Syndromes
  50. (2010). Vral A: Chromosomal radiosensitivity of HIV positive individuals.
  51. (2009). Weitzman MD: Viral manipulation of DNA repair and cell cycle checkpoints. DNA Repair
  52. (2008). WG: Phase I trial of the human immunodeficiency virus protease inhibitor Nelfinavir and chemoradiation for locally advanced pancreatic cancer.
  53. (2002). WH: The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Research
  54. (2010). Zietman A: What is the optimal management of high risk, clinically localized prostate cancer? Urologic Oncology-Seminars and Original Investigations